Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ion Beam ApplicationsIOBCF -3.22%80 Future 3-5Y EPS without NRI Growth Rate is 52.16 as of Sep. 05, 2026. GuruFocus rates IOBCF with a GF Score™ of 80/100 and a GF Value™ of $18.37 (Fairly Valued). The stock has 7 warning signs investors should review. Among 282 Medical Devices & Instruments companies, Ion Beam Applications ranks better than 86.52% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Ion Beam Applications's Future 3-5Y EPS without NRI Growth Rate is 52.16.
Ion Beam Applications (OTCPK:IOBCF) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Ion Beam Applications Future 3-5Y EPS without NRI Growth Rate Related Terms
IOBCF vs ABT, SYK, MDT: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Ion Beam Applications's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ion Beam Applications Future 3-5Y EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ion Beam Applications's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ion Beam Applications's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 52.16 mean?
Ion Beam Applications (IOBCF) has a Future 3-5Y EPS without NRI Growth Rate of 52.16 as of Sep. 05, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Ion Beam Applications and its competitors. According to the industry distribution chart, Ion Beam Applications ranks #38 out of 282 companies in the Medical Devices & Instruments industry, placing it in the top 13.5%.
Is Ion Beam Applications' Future 3-5Y EPS without NRI Growth Rate too high?
Ion Beam Applications' current Future 3-5Y EPS without NRI Growth Rate is 52.16. The Medical Devices & Instruments industry median Future 3-5Y EPS without NRI Growth Rate is 20.70. Ion Beam Applications' value of 52.16 is 152% above this industry median. Based on the distribution chart, Ion Beam Applications ranks #38 out of 282 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Ion Beam Applications has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ion Beam Applications' Future 3-5Y EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ion Beam Applications ranks #38 out of 282 companies for Future 3-5Y EPS without NRI Growth Rate. This places Ion Beam Applications in the top 14% of its industry — outperforming the majority of peers. The industry median Future 3-5Y EPS without NRI Growth Rate is 20.70. Ion Beam Applications' value of 52.16 is 152% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median Future 3-5Y EPS without NRI Growth Rate among Medical Devices & Instruments companies is 20.70, based on 282 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ion Beam Applications's current Future 3-5Y EPS without NRI Growth Rate of 52.16 is 152% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Ion Beam Applications and its competitors. For the Medical Devices & Instruments industry, the median Future 3-5Y EPS without NRI Growth Rate is 20.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ion Beam Applications's current Future 3-5Y EPS without NRI Growth Rate is 52.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ion Beam Applications stock overvalued right now?
Based on GuruFocus' analysis, Ion Beam Applications (IOBCF) is currently considered Fairly Valued. The stock's GF Value™ is $18.37, compared to a current price of $17.91 — trading 2.5% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 52.16 and 152% above the Medical Devices & Instruments industry median of 20.70. Ion Beam Applications' overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Ion Beam Applications (IOBCF), the current Future 3-5Y EPS without NRI Growth Rate is 52.16 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ion Beam Applications (IOBCF) Overvalued in 2026?
Based on GuruFocus' analysis, Ion Beam Applications stock appears to be undervalued.
The current stock price of $17.91 is trading 2.5% below its estimated GF Value™ of $18.37.
GuruFocus considers Ion Beam Applications to be Fairly Valued.
Key valuation signals for IOBCF:
Future 3-5Y EPS without NRI Growth Rate: 52.16
GF Value™: $18.37 vs. price of $17.91 (2.5% below fair value)
Industry Position: 152% above the Medical Devices & Instruments median (#38 of 282)
No single metric tells the full story. See the IOBCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in three segments: IBA Clinical, including Proton Therapy and Dosimetry; IBA Technologies; and IBA Corporate. Proton therapy and other accelerators contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, China, Germany, and India.
80GF Score
Get the complete analysis for IOBCF
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOBCF has been successfully added to your 
